Solubility solutions: Catalent increases spray drying capacity at Pharmatek

By Melissa Fassbender

- Last updated on GMT

Catalent acquired Pharmatek Laboratories, Inc., in September 2016. (Image: Catalent Pharma Solutions)
Catalent acquired Pharmatek Laboratories, Inc., in September 2016. (Image: Catalent Pharma Solutions)

Related tags Pharmacology

Catalent Pharma Solutions is increasing cGMP spray drying capacity at its Pharmatek facility in response to industry demand for improved solubility.

The company has installed an additional GEA Niro Mobile Minor unit and a third Gerties Mini-Pactor.

Validation for cGMP use is expected by the end of April and early May 2017, respectively.

Over 90% of drugs in development have solubility issues, which can compromise a molecule’s bioavailability​,” said Elizabeth Hickman of Pharmatek.

Spray drying is a powerful tool for overcoming bioavailability challenges, and complements Catalent’s existing broad toolkit for the enhancement of drug physiochemical properties​.”

Hickman explained the San Diego-based facility will become the focal point of Catalent’s OptiForm Solution Suite platform, “combining world-leading screening capabilities and innovative drug delivery technologies to accelerate early-stage drug development and enable innovator companies to advance to the clinic sooner​,” she told us.

Catalent acquired Pharmatek in 2016 at which time Outsourcing-Pharma.com reported the addition would expand Catalent’s bioavailability enhancement offering. As Hickman explained, “The acquisition of Pharmatek was strategic, not only to bring spray drying technology to Catalent, but also to enable us to work with companies earlier in the development process, where Pharmatek has significant experience​.”

The company will continue to invest in its global facility network, Hickman added, “Including leading bioavailability enhancement solutions to overcome their challenges and, ultimately, enabling patients to benefit from new and innovative therapies​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars